New Report on Interventional Cardiovascular Device Industry In China 2015

The report “China Interventional Cardiovascular Device Industry Report, 2013-2015″ by Research in China is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on China Interventional Cardiovascular Device Industry Report, 2013-2015 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “China Interventional Cardiovascular Device Industry Report, 2013-2015”On chinamarketresearchreports.com .

Synopsis

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patient’s stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%.

In China, interventional cardiovascular devices are dominated by cardiovascular stent. Currently, the top three companies in China's coronary stent market are respectively MicroPort, Lepu Medical and JW Medical; while supporting auxiliary devices such as catheter and guide wire feature low localization rate, mainly dependent on imports. In 2012, Chinese enterprises accounted for 66.8% of Chinese interventional cardiovascular device market share, followed by foreign counterparts with 33.2%.

Buy a copy of this report by Research in China @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114663 .

Interventional cardiovascular device is a sunrise industry, there lies strong clinical demand for safer and more effective interventional products, and thus the world's major manufacturers have invested heavily in research and development of new products. Bio absorbable everolimus-eluting stent (BVS) has become the focus of attention. Abbott in September 2012 launched the world's first A bio absorbable everolimus-eluting coronary stent system (ABSORB), expected to bring a revolutionary change in coronary artery disease (CAD) treatment; MicroPort's third-generation completely biodegradable drug-eluting stent Firehawk has completed clinical trials in China; Lepu Medical's completely biodegradable drug-eluting stent is also in active research and development.

Complete report spread across [89] pages available @ http://www.chinamarketresearchreports.com/114663.html. Read more on “China Interventional Cardiovascular Device Industry Report, 2013-2015” report below.

China Interventional Cardiovascular Device Industry Report, 2013-2015 mainly covers the followings:

• Development, market demand, competition pattern, profit level, etc. of the industry;
• Policy environment, impacts from upstream and downstream sectors, etc.;
• Market size, supply and demand, product price, etc. of industry segments (including coronary stent, balloon catheter, guide wire, sheath group and auxiliary device), etc.;
• Operation, interventional device cardiovascular business, operation in China, etc. of global companies (including Johnson & Johnson, Medtronic, Boston Scientific, Abbott Laboratories, B. Braun);
• Operation, interventional cardiovascular device business, etc. of Chinese companies (including MicroPort, Lepu Medical, Lifetech Scientific, JW Medical, Liaoning Bio-medical Technology, OrbusNeich, SCW Medicath, Amtech Biotech and Starway Medical).

For further information on “China Interventional Cardiovascular Device Industry Report, 2013-2015” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.